Edwards Lifesciences (NYSE:EW – Get Free Report) had its target price hoisted by investment analysts at Sanford C. Bernstein from $99.00 to $106.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “market perform” rating on the medical research company’s stock. Sanford C. Bernstein‘s target price points to a potential upside of 4.01% from the company’s previous close.
Several other equities research analysts have also recently issued reports on the company. Deutsche Bank Aktiengesellschaft set a $104.00 target price on Edwards Lifesciences in a report on Tuesday, October 27th. Jefferies Financial Group increased their price target on Edwards Lifesciences from $102.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Evercore restated an “outperform” rating on shares of Edwards Lifesciences in a report on Friday, October 23rd. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, The Goldman Sachs Group upped their price objective on Edwards Lifesciences from $98.00 to $102.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $108.88.
Read Our Latest Analysis on EW
Edwards Lifesciences Price Performance
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.67 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 3.01 earnings per share for the current fiscal year.
Insider Activity
In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Edwards Lifesciences
Institutional investors have recently modified their holdings of the stock. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $26,000. TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $27,000. GK Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $26,000. Finally, Compass Financial Management LLC purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at $32,000. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences News Roundup
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
- Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
- Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
- Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.
The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
